| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 52 | 2025 | 503 | 11.500 |
Why?
|
| Oropharyngeal Neoplasms | 24 | 2025 | 165 | 8.960 |
Why?
|
| Carcinoma, Squamous Cell | 39 | 2024 | 668 | 8.350 |
Why?
|
| Papillomavirus Infections | 14 | 2025 | 296 | 3.570 |
Why?
|
| Laryngeal Neoplasms | 8 | 2023 | 84 | 2.970 |
Why?
|
| Metformin | 8 | 2023 | 151 | 2.500 |
Why?
|
| Veterans | 14 | 2023 | 1748 | 2.450 |
Why?
|
| Thyroid Neoplasms | 10 | 2021 | 189 | 2.160 |
Why?
|
| Antineoplastic Agents | 13 | 2024 | 1691 | 2.160 |
Why?
|
| Osteoradionecrosis | 4 | 2025 | 13 | 2.050 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 7 | 2021 | 16 | 1.700 |
Why?
|
| Fibroblasts | 13 | 2011 | 888 | 1.690 |
Why?
|
| Laryngectomy | 7 | 2023 | 26 | 1.630 |
Why?
|
| Dinoprostone | 11 | 2022 | 77 | 1.470 |
Why?
|
| Mouth | 3 | 2021 | 62 | 1.420 |
Why?
|
| Mouth Neoplasms | 4 | 2022 | 84 | 1.410 |
Why?
|
| Tumor Suppressor Protein p53 | 11 | 2024 | 723 | 1.400 |
Why?
|
| Wound Healing | 16 | 2019 | 460 | 1.320 |
Why?
|
| Biomarkers, Tumor | 12 | 2023 | 1496 | 1.310 |
Why?
|
| Deglutition Disorders | 3 | 2019 | 132 | 1.230 |
Why?
|
| Lactic Acid | 4 | 2018 | 153 | 1.210 |
Why?
|
| Papillomaviridae | 7 | 2022 | 144 | 1.130 |
Why?
|
| Cell Line, Tumor | 23 | 2025 | 3348 | 1.120 |
Why?
|
| Hypoglycemic Agents | 5 | 2021 | 444 | 1.120 |
Why?
|
| Oxidative Stress | 3 | 2025 | 837 | 1.070 |
Why?
|
| Cisplatin | 7 | 2024 | 249 | 1.000 |
Why?
|
| Humans | 116 | 2025 | 125189 | 0.990 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2023 | 1140 | 0.970 |
Why?
|
| Glottis | 7 | 2019 | 31 | 0.960 |
Why?
|
| Neoplasm Staging | 7 | 2020 | 1275 | 0.940 |
Why?
|
| Smoke | 1 | 2025 | 60 | 0.920 |
Why?
|
| Chemoradiotherapy | 6 | 2018 | 103 | 0.910 |
Why?
|
| Risk Assessment | 7 | 2025 | 3465 | 0.880 |
Why?
|
| Immunity | 1 | 2025 | 192 | 0.880 |
Why?
|
| Tumor Microenvironment | 8 | 2025 | 557 | 0.870 |
Why?
|
| Retrospective Studies | 36 | 2025 | 16353 | 0.860 |
Why?
|
| Cell Movement | 9 | 2014 | 847 | 0.860 |
Why?
|
| Pyruvic Acid | 5 | 2018 | 38 | 0.840 |
Why?
|
| NF-E2-Related Factor 2 | 5 | 2025 | 114 | 0.830 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2023 | 22 | 0.830 |
Why?
|
| Free Tissue Flaps | 6 | 2024 | 51 | 0.820 |
Why?
|
| Disease-Free Survival | 11 | 2021 | 897 | 0.790 |
Why?
|
| Prognosis | 16 | 2023 | 4645 | 0.770 |
Why?
|
| Gastrostomy | 2 | 2019 | 86 | 0.770 |
Why?
|
| Carcinoma | 6 | 2023 | 287 | 0.750 |
Why?
|
| Middle Aged | 41 | 2025 | 26927 | 0.740 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2021 | 27 | 0.730 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 1659 | 0.720 |
Why?
|
| CD8 Antigens | 2 | 2020 | 41 | 0.700 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2024 | 723 | 0.700 |
Why?
|
| Neoplasms | 7 | 2023 | 2790 | 0.700 |
Why?
|
| Aged | 34 | 2025 | 19870 | 0.690 |
Why?
|
| Veterans Health | 1 | 2021 | 176 | 0.650 |
Why?
|
| Oxidative Phosphorylation | 1 | 2020 | 107 | 0.650 |
Why?
|
| Salvage Therapy | 3 | 2023 | 192 | 0.650 |
Why?
|
| Mice, Nude | 10 | 2023 | 708 | 0.620 |
Why?
|
| Laryngostenosis | 5 | 2014 | 37 | 0.600 |
Why?
|
| Larynx, Artificial | 1 | 2018 | 4 | 0.600 |
Why?
|
| Male | 52 | 2025 | 61525 | 0.600 |
Why?
|
| Voice Quality | 1 | 2018 | 19 | 0.590 |
Why?
|
| Radiation Tolerance | 3 | 2015 | 48 | 0.580 |
Why?
|
| Combined Modality Therapy | 9 | 2023 | 1242 | 0.570 |
Why?
|
| Deoxyglucose | 3 | 2012 | 33 | 0.570 |
Why?
|
| Reactive Oxygen Species | 5 | 2017 | 499 | 0.570 |
Why?
|
| Carbon Isotopes | 3 | 2015 | 277 | 0.570 |
Why?
|
| Smoking | 3 | 2020 | 1051 | 0.570 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2025 | 1893 | 0.570 |
Why?
|
| Carbon | 1 | 2018 | 92 | 0.570 |
Why?
|
| Lymph Nodes | 3 | 2018 | 379 | 0.560 |
Why?
|
| Survival Analysis | 7 | 2020 | 1506 | 0.560 |
Why?
|
| Mandible | 3 | 2023 | 79 | 0.560 |
Why?
|
| Alphapapillomavirus | 3 | 2022 | 30 | 0.560 |
Why?
|
| Neoplasm, Residual | 3 | 2018 | 122 | 0.560 |
Why?
|
| Female | 49 | 2025 | 66806 | 0.550 |
Why?
|
| Radiotherapy, Adjuvant | 7 | 2024 | 144 | 0.530 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2022 | 101 | 0.530 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2016 | 43 | 0.520 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 425 | 0.510 |
Why?
|
| Collagen | 7 | 2011 | 320 | 0.500 |
Why?
|
| Disease Management | 1 | 2019 | 528 | 0.490 |
Why?
|
| Mutation | 5 | 2018 | 5845 | 0.490 |
Why?
|
| Vocal Cords | 5 | 2020 | 66 | 0.480 |
Why?
|
| Animals | 32 | 2025 | 34232 | 0.460 |
Why?
|
| Mice | 18 | 2025 | 17631 | 0.440 |
Why?
|
| Lymphatic Metastasis | 5 | 2024 | 418 | 0.440 |
Why?
|
| Time-to-Treatment | 4 | 2024 | 188 | 0.440 |
Why?
|
| Glycolysis | 5 | 2018 | 150 | 0.430 |
Why?
|
| Interleukin-1beta | 4 | 2012 | 162 | 0.430 |
Why?
|
| Follow-Up Studies | 10 | 2021 | 5176 | 0.430 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2020 | 618 | 0.420 |
Why?
|
| Neoplasm Invasiveness | 5 | 2021 | 620 | 0.410 |
Why?
|
| Glucose | 2 | 2023 | 877 | 0.410 |
Why?
|
| Quality of Life | 3 | 2022 | 1934 | 0.400 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2024 | 3573 | 0.390 |
Why?
|
| Rabbits | 10 | 2012 | 718 | 0.390 |
Why?
|
| Survival Rate | 9 | 2021 | 2062 | 0.380 |
Why?
|
| Mutant Proteins | 1 | 2011 | 114 | 0.360 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2023 | 55 | 0.350 |
Why?
|
| Mucous Membrane | 4 | 2012 | 89 | 0.330 |
Why?
|
| Cohort Studies | 8 | 2022 | 4817 | 0.330 |
Why?
|
| Glutamine | 1 | 2011 | 215 | 0.320 |
Why?
|
| Precision Medicine | 2 | 2023 | 319 | 0.320 |
Why?
|
| Mitochondria | 4 | 2020 | 680 | 0.310 |
Why?
|
| Treatment Outcome | 14 | 2023 | 12392 | 0.310 |
Why?
|
| Adult | 24 | 2025 | 29628 | 0.310 |
Why?
|
| Diabetes Mellitus | 2 | 2014 | 874 | 0.300 |
Why?
|
| Risk | 2 | 2021 | 756 | 0.300 |
Why?
|
| Hematoxylin | 2 | 2025 | 8 | 0.290 |
Why?
|
| Eosine Yellowish-(YS) | 2 | 2025 | 9 | 0.290 |
Why?
|
| Prospective Studies | 6 | 2025 | 6153 | 0.290 |
Why?
|
| United States | 10 | 2025 | 10915 | 0.290 |
Why?
|
| Trachea | 1 | 2009 | 203 | 0.280 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2015 | 1056 | 0.280 |
Why?
|
| Multivariate Analysis | 4 | 2016 | 1438 | 0.280 |
Why?
|
| Proportional Hazards Models | 6 | 2018 | 1360 | 0.270 |
Why?
|
| Keloid | 1 | 2007 | 10 | 0.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2022 | 1251 | 0.270 |
Why?
|
| Diet | 3 | 2025 | 1140 | 0.270 |
Why?
|
| Radiation, Ionizing | 3 | 2015 | 41 | 0.260 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 2 | 2023 | 28 | 0.260 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2021 | 889 | 0.260 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2023 | 118 | 0.250 |
Why?
|
| Tongue Neoplasms | 2 | 2019 | 19 | 0.250 |
Why?
|
| Paraffin Embedding | 1 | 2025 | 33 | 0.240 |
Why?
|
| Cell Communication | 2 | 2008 | 167 | 0.240 |
Why?
|
| Formaldehyde | 1 | 2025 | 36 | 0.240 |
Why?
|
| Tissue Fixation | 1 | 2025 | 38 | 0.240 |
Why?
|
| Employment | 1 | 2025 | 69 | 0.230 |
Why?
|
| Glossectomy | 2 | 2021 | 7 | 0.230 |
Why?
|
| Disease Models, Animal | 8 | 2021 | 4395 | 0.230 |
Why?
|
| Staining and Labeling | 1 | 2025 | 187 | 0.230 |
Why?
|
| Lip Neoplasms | 1 | 2024 | 4 | 0.220 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2024 | 37 | 0.220 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2024 | 65 | 0.220 |
Why?
|
| Mammary Analogue Secretory Carcinoma | 1 | 2023 | 8 | 0.220 |
Why?
|
| Patient Navigation | 1 | 2023 | 25 | 0.210 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2015 | 294 | 0.210 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2021 | 62 | 0.210 |
Why?
|
| Cell Culture Techniques | 4 | 2011 | 281 | 0.210 |
Why?
|
| Fetus | 5 | 2009 | 585 | 0.210 |
Why?
|
| Head | 1 | 2023 | 103 | 0.200 |
Why?
|
| Glutathione Peroxidase | 1 | 2022 | 53 | 0.200 |
Why?
|
| Skin | 2 | 2019 | 519 | 0.200 |
Why?
|
| Deglutition | 2 | 2019 | 51 | 0.200 |
Why?
|
| Larynx | 1 | 2023 | 72 | 0.190 |
Why?
|
| Hospitals, Veterans | 2 | 2015 | 359 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2025 | 2107 | 0.190 |
Why?
|
| Minority Groups | 2 | 2023 | 249 | 0.190 |
Why?
|
| Cancer Survivors | 1 | 2025 | 211 | 0.190 |
Why?
|
| Papillomavirus Vaccines | 1 | 2023 | 94 | 0.190 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2021 | 584 | 0.190 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 242 | 0.190 |
Why?
|
| Spouses | 2 | 2019 | 67 | 0.180 |
Why?
|
| Organ Transplantation | 1 | 2023 | 168 | 0.180 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 667 | 0.180 |
Why?
|
| Extracellular Matrix | 4 | 2011 | 238 | 0.180 |
Why?
|
| High-Throughput Screening Assays | 1 | 2021 | 97 | 0.180 |
Why?
|
| Leukoplakia | 1 | 2020 | 3 | 0.180 |
Why?
|
| Laryngeal Diseases | 1 | 2020 | 32 | 0.170 |
Why?
|
| Mandibular Diseases | 1 | 2020 | 9 | 0.170 |
Why?
|
| Pharyngeal Diseases | 1 | 2020 | 19 | 0.170 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 361 | 0.170 |
Why?
|
| Genes, p53 | 2 | 2011 | 212 | 0.170 |
Why?
|
| Cutaneous Fistula | 1 | 2020 | 23 | 0.170 |
Why?
|
| Databases, Genetic | 2 | 2020 | 474 | 0.170 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2020 | 23 | 0.170 |
Why?
|
| Stress, Psychological | 1 | 2025 | 559 | 0.170 |
Why?
|
| Feasibility Studies | 5 | 2021 | 761 | 0.170 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2023 | 237 | 0.170 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2019 | 2 | 0.170 |
Why?
|
| Caregivers | 1 | 2025 | 574 | 0.160 |
Why?
|
| Radiodermatitis | 1 | 2019 | 7 | 0.160 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2020 | 70 | 0.160 |
Why?
|
| Signal Transduction | 6 | 2023 | 4534 | 0.160 |
Why?
|
| HIV Infections | 2 | 2022 | 1899 | 0.160 |
Why?
|
| Thyroidectomy | 2 | 2017 | 100 | 0.160 |
Why?
|
| Interleukin-12 | 1 | 2020 | 116 | 0.160 |
Why?
|
| HIV | 1 | 2020 | 180 | 0.160 |
Why?
|
| Length of Stay | 2 | 2024 | 1310 | 0.160 |
Why?
|
| Antibodies, Bispecific | 1 | 2020 | 38 | 0.160 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2021 | 188 | 0.160 |
Why?
|
| Radiotherapy Dosage | 2 | 2016 | 183 | 0.160 |
Why?
|
| Administration, Topical | 1 | 2019 | 139 | 0.160 |
Why?
|
| Esomeprazole | 1 | 2019 | 32 | 0.160 |
Why?
|
| Cicatrix | 3 | 2012 | 124 | 0.160 |
Why?
|
| Cyclooxygenase 2 | 2 | 2010 | 155 | 0.160 |
Why?
|
| Fibrosis | 2 | 2019 | 436 | 0.160 |
Why?
|
| Oncolytic Viruses | 1 | 2020 | 73 | 0.160 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 362 | 0.160 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2019 | 38 | 0.160 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 6598 | 0.160 |
Why?
|
| Sexual Partners | 1 | 2019 | 87 | 0.160 |
Why?
|
| Oncolytic Virotherapy | 1 | 2020 | 85 | 0.150 |
Why?
|
| Family Conflict | 1 | 2018 | 18 | 0.150 |
Why?
|
| Dermis | 3 | 2007 | 24 | 0.150 |
Why?
|
| DNA, Mitochondrial | 1 | 2020 | 211 | 0.150 |
Why?
|
| Databases, Nucleic Acid | 1 | 2019 | 70 | 0.150 |
Why?
|
| Radiation Injuries | 2 | 2020 | 142 | 0.150 |
Why?
|
| Morbidity | 1 | 2019 | 249 | 0.150 |
Why?
|
| Respiratory Mucosa | 2 | 2010 | 91 | 0.150 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2010 | 824 | 0.150 |
Why?
|
| Incidence | 3 | 2022 | 3147 | 0.150 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2018 | 43 | 0.150 |
Why?
|
| Time Factors | 7 | 2025 | 6338 | 0.140 |
Why?
|
| Citric Acid Cycle | 1 | 2018 | 47 | 0.140 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2016 | 65 | 0.140 |
Why?
|
| Comorbidity | 1 | 2022 | 1534 | 0.140 |
Why?
|
| Radiopharmaceuticals | 2 | 2015 | 168 | 0.140 |
Why?
|
| Cell Proliferation | 4 | 2014 | 2311 | 0.140 |
Why?
|
| Radiotherapy | 3 | 2019 | 135 | 0.140 |
Why?
|
| Platinum Compounds | 1 | 2017 | 6 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 541 | 0.140 |
Why?
|
| Self-Management | 1 | 2018 | 99 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2020 | 333 | 0.140 |
Why?
|
| Adenoviridae | 1 | 2020 | 606 | 0.140 |
Why?
|
| DNA Damage | 2 | 2022 | 513 | 0.140 |
Why?
|
| Interleukin-1 | 2 | 2009 | 142 | 0.130 |
Why?
|
| Contrast Media | 1 | 2020 | 480 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 3 | 2014 | 1065 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 363 | 0.130 |
Why?
|
| Skin Neoplasms | 1 | 2023 | 862 | 0.130 |
Why?
|
| Pharyngeal Muscles | 1 | 2016 | 11 | 0.130 |
Why?
|
| Carbon Radioisotopes | 1 | 2015 | 71 | 0.120 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2016 | 57 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 686 | 0.120 |
Why?
|
| Metabolism | 1 | 2015 | 42 | 0.120 |
Why?
|
| Receptors, Estrogen | 1 | 2019 | 794 | 0.120 |
Why?
|
| Adenocarcinoma | 2 | 2013 | 1026 | 0.120 |
Why?
|
| Risk Factors | 5 | 2025 | 10315 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2015 | 81 | 0.120 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 71 | 0.120 |
Why?
|
| Carcinogens | 1 | 2015 | 152 | 0.120 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 949 | 0.120 |
Why?
|
| Tracheal Stenosis | 1 | 2014 | 31 | 0.110 |
Why?
|
| Blotting, Western | 4 | 2011 | 1102 | 0.110 |
Why?
|
| Laser Therapy | 2 | 2007 | 249 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1272 | 0.110 |
Why?
|
| Fluoresceins | 1 | 2014 | 35 | 0.110 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2013 | 22 | 0.110 |
Why?
|
| Texas | 4 | 2020 | 3588 | 0.110 |
Why?
|
| Gels | 3 | 2009 | 69 | 0.110 |
Why?
|
| Heterografts | 1 | 2014 | 173 | 0.110 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 832 | 0.110 |
Why?
|
| Inflammation | 2 | 2019 | 1446 | 0.110 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2013 | 54 | 0.100 |
Why?
|
| Cell Death | 1 | 2014 | 239 | 0.100 |
Why?
|
| Metabolomics | 2 | 2021 | 423 | 0.100 |
Why?
|
| Radiographic Image Enhancement | 1 | 2013 | 42 | 0.100 |
Why?
|
| Alcoholism | 1 | 2015 | 231 | 0.100 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 443 | 0.100 |
Why?
|
| Neck Dissection | 1 | 2012 | 18 | 0.100 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2014 | 161 | 0.100 |
Why?
|
| Cancer Care Facilities | 1 | 2012 | 31 | 0.100 |
Why?
|
| Cells, Cultured | 5 | 2010 | 3056 | 0.100 |
Why?
|
| RNA, Messenger | 3 | 2010 | 2820 | 0.100 |
Why?
|
| Transplantation, Heterologous | 3 | 2014 | 256 | 0.100 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2012 | 57 | 0.100 |
Why?
|
| Tonsillectomy | 1 | 2013 | 99 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2013 | 252 | 0.100 |
Why?
|
| Rectal Neoplasms | 1 | 2013 | 78 | 0.090 |
Why?
|
| Cesium Radioisotopes | 1 | 2011 | 4 | 0.090 |
Why?
|
| Flow Cytometry | 1 | 2014 | 797 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 880 | 0.090 |
Why?
|
| Glucose Transport Proteins, Facilitative | 1 | 2011 | 14 | 0.090 |
Why?
|
| Oncogene Protein v-akt | 1 | 2011 | 30 | 0.090 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2011 | 8 | 0.090 |
Why?
|
| Diabetes Complications | 1 | 2012 | 203 | 0.090 |
Why?
|
| Receptors, Prostaglandin | 2 | 2010 | 22 | 0.090 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2011 | 129 | 0.090 |
Why?
|
| Oxygen Consumption | 1 | 2011 | 305 | 0.090 |
Why?
|
| Poverty | 1 | 2013 | 425 | 0.090 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2013 | 206 | 0.080 |
Why?
|
| Chromatography, Liquid | 1 | 2011 | 196 | 0.080 |
Why?
|
| Adenosine Triphosphate | 1 | 2011 | 282 | 0.080 |
Why?
|
| Mitochondrial Proteins | 1 | 2011 | 228 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 1290 | 0.080 |
Why?
|
| Phenotype | 2 | 2011 | 4262 | 0.080 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 332 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2023 | 468 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 3425 | 0.080 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2009 | 59 | 0.080 |
Why?
|
| Granulation Tissue | 2 | 2005 | 13 | 0.080 |
Why?
|
| Cyclic AMP | 2 | 2007 | 246 | 0.080 |
Why?
|
| Energy Metabolism | 1 | 2014 | 766 | 0.080 |
Why?
|
| Carbon Dioxide | 2 | 2007 | 279 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 335 | 0.080 |
Why?
|
| Immunohistochemistry | 3 | 2025 | 1693 | 0.080 |
Why?
|
| Databases, Factual | 3 | 2020 | 1179 | 0.080 |
Why?
|
| Lasers | 1 | 2009 | 114 | 0.080 |
Why?
|
| Phosphoproteins | 1 | 2011 | 418 | 0.080 |
Why?
|
| Connexin 43 | 1 | 2008 | 29 | 0.080 |
Why?
|
| Focal Adhesions | 1 | 2008 | 14 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2011 | 383 | 0.080 |
Why?
|
| Gap Junctions | 1 | 2008 | 38 | 0.080 |
Why?
|
| Lasers, Gas | 1 | 2008 | 7 | 0.080 |
Why?
|
| Cell Cycle | 1 | 2011 | 617 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2018 | 1396 | 0.070 |
Why?
|
| Tissue Distribution | 2 | 2022 | 391 | 0.070 |
Why?
|
| Young Adult | 6 | 2020 | 9053 | 0.070 |
Why?
|
| Esophageal Neoplasms | 1 | 2012 | 376 | 0.070 |
Why?
|
| Constriction, Pathologic | 2 | 2005 | 240 | 0.070 |
Why?
|
| Proteomics | 1 | 2011 | 502 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 2 | 2021 | 515 | 0.070 |
Why?
|
| Cell Survival | 2 | 2014 | 813 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2007 | 343 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2009 | 867 | 0.070 |
Why?
|
| Algorithms | 3 | 2021 | 1629 | 0.060 |
Why?
|
| Adaptation, Psychological | 2 | 2019 | 448 | 0.060 |
Why?
|
| RNA, Small Interfering | 2 | 2021 | 663 | 0.060 |
Why?
|
| Voice Disorders | 1 | 2005 | 18 | 0.060 |
Why?
|
| Mouth Mucosa | 1 | 2005 | 52 | 0.060 |
Why?
|
| Genomics | 1 | 2013 | 1499 | 0.060 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2019 | 117 | 0.060 |
Why?
|
| Splenectomy | 1 | 2005 | 65 | 0.060 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2025 | 37 | 0.060 |
Why?
|
| Statistics, Nonparametric | 2 | 2020 | 435 | 0.060 |
Why?
|
| Disease Progression | 1 | 2011 | 2067 | 0.060 |
Why?
|
| Aging | 1 | 2011 | 1181 | 0.060 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2005 | 55 | 0.060 |
Why?
|
| Reproducibility of Results | 4 | 2013 | 2891 | 0.060 |
Why?
|
| Nutrition Policy | 1 | 2025 | 102 | 0.060 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2024 | 13 | 0.060 |
Why?
|
| Anoctamin-1 | 1 | 2024 | 3 | 0.060 |
Why?
|
| Observer Variation | 1 | 2025 | 299 | 0.060 |
Why?
|
| Skull Base | 1 | 2024 | 53 | 0.060 |
Why?
|
| Pneumothorax | 1 | 2005 | 76 | 0.050 |
Why?
|
| Immunomodulation | 1 | 2024 | 79 | 0.050 |
Why?
|
| Gingiva | 1 | 2023 | 9 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2017 | 341 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 1586 | 0.050 |
Why?
|
| Immunogenetics | 1 | 2023 | 8 | 0.050 |
Why?
|
| Gene Fusion | 1 | 2023 | 55 | 0.050 |
Why?
|
| ROC Curve | 1 | 2025 | 569 | 0.050 |
Why?
|
| Tensile Strength | 1 | 2003 | 40 | 0.050 |
Why?
|
| Biomarkers | 2 | 2022 | 3091 | 0.050 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2023 | 23 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2024 | 240 | 0.050 |
Why?
|
| Analysis of Variance | 3 | 2011 | 1020 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2024 | 4404 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1271 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2025 | 355 | 0.050 |
Why?
|
| Models, Biological | 1 | 2007 | 1460 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2003 | 300 | 0.050 |
Why?
|
| Prevalence | 2 | 2023 | 2458 | 0.050 |
Why?
|
| Apoptosis | 2 | 2024 | 1806 | 0.050 |
Why?
|
| Ubiquitin-Specific Peptidase 7 | 1 | 2022 | 17 | 0.050 |
Why?
|
| Epigenomics | 1 | 2023 | 164 | 0.050 |
Why?
|
| Postoperative Care | 1 | 2024 | 301 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2024 | 278 | 0.050 |
Why?
|
| Carcinogenicity Tests | 1 | 2021 | 20 | 0.050 |
Why?
|
| Postoperative Complications | 3 | 2022 | 3073 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 762 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2003 | 262 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2023 | 210 | 0.050 |
Why?
|
| Calcium-Binding Proteins | 1 | 2023 | 326 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2023 | 358 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1324 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 2 | 2011 | 258 | 0.050 |
Why?
|
| Ubiquitin | 1 | 2022 | 141 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2003 | 667 | 0.050 |
Why?
|
| Neck | 1 | 2022 | 135 | 0.050 |
Why?
|
| Laryngoscopy | 3 | 2008 | 151 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 872 | 0.040 |
Why?
|
| Pharyngectomy | 1 | 2020 | 3 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2022 | 480 | 0.040 |
Why?
|
| Models, Animal | 1 | 2022 | 464 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2020 | 233 | 0.040 |
Why?
|
| Blood Vessels | 1 | 2020 | 104 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2005 | 493 | 0.040 |
Why?
|
| Hyaluronan Receptors | 1 | 2020 | 66 | 0.040 |
Why?
|
| Transcription, Genetic | 2 | 2019 | 1699 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2021 | 359 | 0.040 |
Why?
|
| Composite Tissue Allografts | 1 | 2019 | 2 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2021 | 256 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2007 | 3299 | 0.040 |
Why?
|
| SEER Program | 1 | 2020 | 202 | 0.040 |
Why?
|
| Heme Oxygenase-1 | 1 | 2019 | 36 | 0.040 |
Why?
|
| Swine | 1 | 2003 | 1210 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 286 | 0.040 |
Why?
|
| Feeding Methods | 1 | 2019 | 37 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 356 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2015 | 1631 | 0.040 |
Why?
|
| Neuroblastoma | 1 | 2024 | 526 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2020 | 569 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2021 | 699 | 0.040 |
Why?
|
| Models, Anatomic | 1 | 2019 | 99 | 0.040 |
Why?
|
| Telephone | 1 | 2018 | 110 | 0.040 |
Why?
|
| Disclosure | 1 | 2019 | 150 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 2057 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 678 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 581 | 0.040 |
Why?
|
| Cytochrome c Group | 1 | 2017 | 17 | 0.040 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2017 | 24 | 0.040 |
Why?
|
| Electron Transport Complex IV | 1 | 2017 | 39 | 0.040 |
Why?
|
| Vaccination | 1 | 2023 | 963 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2018 | 230 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 293 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 2018 | 184 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2022 | 1022 | 0.030 |
Why?
|
| Emotions | 1 | 2019 | 356 | 0.030 |
Why?
|
| Palate, Soft | 1 | 2016 | 16 | 0.030 |
Why?
|
| Cell Line | 2 | 2011 | 2756 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2021 | 680 | 0.030 |
Why?
|
| Analog-Digital Conversion | 1 | 2015 | 2 | 0.030 |
Why?
|
| Propensity Score | 1 | 2016 | 216 | 0.030 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2015 | 41 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2015 | 149 | 0.030 |
Why?
|
| Enzymes | 1 | 2015 | 51 | 0.030 |
Why?
|
| Hospitals, Military | 1 | 2015 | 10 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 3729 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 308 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 239 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2015 | 162 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 615 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 419 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2015 | 134 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2015 | 50 | 0.030 |
Why?
|
| Hydrogen Peroxide | 1 | 2015 | 112 | 0.030 |
Why?
|
| Protein Transport | 1 | 2016 | 368 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2015 | 311 | 0.030 |
Why?
|
| Ribosomal Protein S6 | 1 | 2014 | 13 | 0.030 |
Why?
|
| Cognition | 1 | 2019 | 728 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 2048 | 0.030 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2014 | 17 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2014 | 57 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2014 | 128 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 2015 | 161 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 376 | 0.030 |
Why?
|
| Equipment Design | 1 | 2015 | 599 | 0.030 |
Why?
|
| Kinetics | 1 | 2015 | 1333 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2015 | 363 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2013 | 29 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2014 | 627 | 0.030 |
Why?
|
| Celecoxib | 1 | 2012 | 32 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 183 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1711 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 854 | 0.020 |
Why?
|
| RNA Interference | 1 | 2014 | 502 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2015 | 346 | 0.020 |
Why?
|
| Tracheostomy | 1 | 2014 | 197 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2019 | 1527 | 0.020 |
Why?
|
| Esophagectomy | 1 | 2012 | 64 | 0.020 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2011 | 25 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2011 | 38 | 0.020 |
Why?
|
| Age Factors | 1 | 2018 | 2823 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 309 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 459 | 0.020 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2011 | 120 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 341 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2012 | 271 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2011 | 101 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 683 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2011 | 149 | 0.020 |
Why?
|
| Protein Binding | 1 | 2014 | 1756 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2012 | 305 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 240 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2011 | 398 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2011 | 276 | 0.020 |
Why?
|
| Adolescent | 2 | 2023 | 19363 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1897 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 983 | 0.020 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2008 | 21 | 0.020 |
Why?
|
| Laryngeal Cartilages | 1 | 2008 | 3 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 461 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2011 | 1243 | 0.020 |
Why?
|
| Capillaries | 1 | 2008 | 66 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2010 | 459 | 0.020 |
Why?
|
| Carboplatin | 1 | 2007 | 76 | 0.020 |
Why?
|
| Time | 1 | 2007 | 92 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2008 | 388 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2007 | 130 | 0.020 |
Why?
|
| Brachytherapy | 1 | 2007 | 75 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 2913 | 0.020 |
Why?
|
| Laryngeal Mucosa | 1 | 2005 | 2 | 0.020 |
Why?
|
| Regeneration | 1 | 2008 | 214 | 0.020 |
Why?
|
| Spherocytosis, Hereditary | 1 | 2005 | 8 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2005 | 104 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2008 | 772 | 0.020 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2005 | 49 | 0.010 |
Why?
|
| Pleurodesis | 1 | 2005 | 16 | 0.010 |
Why?
|
| Rupture, Spontaneous | 1 | 2005 | 49 | 0.010 |
Why?
|
| Blister | 1 | 2005 | 21 | 0.010 |
Why?
|
| Rats | 1 | 2011 | 3727 | 0.010 |
Why?
|
| Random Allocation | 1 | 2005 | 441 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2008 | 1197 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2005 | 510 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 2522 | 0.010 |
Why?
|
| Recurrence | 1 | 2005 | 1420 | 0.010 |
Why?
|
| Child | 2 | 2005 | 24421 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2005 | 14027 | 0.000 |
Why?
|